Cannabinoid CB1 receptor activation does not prevent the toxicity of glutamate towards embryonic chick telencephalon primary cultures

Comparative Biochemistry and Physiology - C Toxicology and Pharmacology

Volumn 136, Issue 3, 2003, Pages 245-251

  Nilsson, Olov ^a   Jacobsson, Stig O P ^a   Fowler, Christopher J ^a  

^a UMEÅ UNIVERSITY   (Sweden)

Author keywords

Anandamide; Cannabinoid receptors; Chick; Excitotoxicity; Primary neuronal culture

Indexed keywords

1 (2,4 DICHLOROPHENYL) 5 (4 IODOPHENYL) 4 METHYL N (1 PIPERIDYL) 1H PYRAZOLE 3 CARBOXAMIDE; 4 (1,1 DIMETHYLHEPTYL) 1',2',3',4',5',6' HEXAHYDRO 2,3' DIHYDROXY 6' (3 HYDROXYPROPYL)BIPHENYL; ANANDAMIDE; BUCLADESINE; CANNABINOID RECEPTOR; CYCLIC AMP; DIZOCILPINE; FORSKOLIN; GLUTAMIC ACID; LACTATE DEHYDROGENASE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; PALMIDROL; 4 PHOSPHONOMETHYLPIPECOLIC ACID; AMIDE; AMINO ACID RECEPTOR BLOCKING AGENT; ARACHIDONIC ACID DERIVATIVE; CANNABINOID; CANNABINOID 1 RECEPTOR; CYCLOHEXANOL DERIVATIVE; DIZOCILPINE MALEATE; PIPECOLIC ACID DERIVATIVE; PIPERIDINE DERIVATIVE; PYRAZOLE DERIVATIVE;

ANIMAL CELL; ARTICLE; CELL CULTURE; CHICK EMBRYO; CULTURE MEDIUM; DOSE RESPONSE; ENZYME RELEASE; IN VITRO STUDY; INCUBATION TIME; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; TELENCEPHALON; ANIMAL; ANIMAL MODEL; BIOSYNTHESIS; DRUG ANTAGONISM; DRUG COMBINATION; DRUG EFFECT; METABOLISM; NERVE CELL; PATHOLOGY; PRENATAL DEVELOPMENT;

RODENTIA;

ANIMALS; ARACHIDONIC ACIDS; CANNABINOIDS; CELLS, CULTURED; CHICK EMBRYO; CYCLIC AMP; CYCLOHEXANOLS; DIZOCILPINE MALEATE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG COMBINATIONS; EXCITATORY AMINO ACID ANTAGONISTS; FORSKOLIN; GLUTAMIC ACID; L-LACTATE DEHYDROGENASE; MODELS, ANIMAL; NEURONS; PIPECOLIC ACIDS; PIPERIDINES; POLYUNSATURATED ALKAMIDES; PYRAZOLES; RECEPTOR, CANNABINOID, CB1; TELENCEPHALON;

EID: 0344628666     PISSN: 15320456     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1532-0456(03)00228-X     Document Type: Article

References (35)

1. Andersson M., Jacobsson S.O.P., Jonsson K.-O., Tiger G., Fowler C.J. Neurotoxicity of glutamate in chick telencephalon neurons. Reduction of toxicity by preincubation with carbachol, but not by the endogenous fatty acid amides anandamide and palmitoylethanolamide. Arch. Toxicol. 74:2000;161-164.
2. Blomqvist P., Lindvall O., Stenevi U., Wieloch T. Cyclic AMP concentrations in rat neocortex and hippocampus during and following incomplete ischemia: effects of central noradrenergic neurons, prostaglandins and adenosine. J. Neurochem. 44:1985;1345-1353.
3. Cota D., Marsicano G., Lutz B., Vicennati V., Stalla G.K., Pasquali R., et al. Endogenous cannabinoid system as a modulator of food intake. Int. J. Obesity. 27:2003;289-301.
4. Dawson G. Mechanisms of apoptosis in embryonic cortical neurons (E6 and E7) in culture involve lipid signalling, protein phosphorylation and caspase activation. Int. J. Dev. Neurosci. 18:2000;247-257.
5. Fernández-Ruiz J., Lastres-Becker I., Cabranes A., González S., Ramos J.A. Endocannabinoids and basal ganglia functionality. Prostag. Leukotr. Ess. Fatty Acids. 66:2002;257-267.
6. Fowler C.J. Plant-derived, synthetic and endogenous cannabinoids as neuroprotective agents. Non-psychoactive cannabinoids, 'entourage' compounds and inhibitors of N-acyl ethanolamine breakdown as therapeutic strategies to avoid pyschotropic effects. Brain Res. Rev. 41:2003;26-43.
7. Fowler C.J., Börjesson M., Tiger G. Differences in the pharmacological properties of rat and chicken brain fatty acid amidohydrolase. Br. J. Pharmacol. 131:2000;498-504.
8. 2 receptor-like immunoreactivity in the embryonic chick brain. Pharmacol. Toxicol. 88:2001;213-222.
9. Hampson A.J., Grimaldi M. Cannabinoid receptor activation and elevated cyclic AMP reduce glutamate neurotoxicity. Eur. J. Neurosci. 13:2001;1529-1536.
10. 9-tetrahydro-cannabinol are neuroprotective antioxidants. Proc. Natl. Acad. Sci. USA. 95:1998;8268-8273.
11. 1 receptor function protects against in vivo disseminating brain damage following NMDA-induced excitotoxicity. J. Neurochem. 82:2002;154-158.
12. Hansen H.H., Schmid P.C., Bittigau P., Lastres-Becker I., Berrendero F., Manzanares J., et al. Anandamide, but not 2-arachidonoylglycerol, accumulates during in vivo neurodegeneration. J. Neurochem. 78:2001;1415-1427.
13. Howlett A.C., Barth F., Bonner T.I., Cabral G., Casellas P., Devane W.A., et al. International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol. Rev. 54:2002;161-202.
14. 1-selective cannabinoid receptor antagonist SR141716. Arch. Gen. Psychiat. 58:2001;322-328.
15. Jacobsson S.O.P., Fowler C.J. Dopamine and glutamate neurotoxicity in cultured chick telencephali cells: effects of NMDA antagonists, antioxidants and MAO inhibitors. Neurochem. Int. 34:1999;49-62.
16. Jacobsson S.O., Hedin H., Sellstrom Å., Fowler C.J. Characterization of the N-methyl-D-aspartate (NMDA) receptor in the embryonic chick brain. Naunyn-Schmiedeberg's Arch. Pharmacol. 357:1998;625-633.
17. Louw D.F., Yang F.W., Sutherland G.R. The effect of δ-9- tetrahydrocannabinol on forebrain ischemia in rat. Brain Res. 857:2000;183-187.
18. 1. J. Neurochem. 80:2002;448-456.
19. Mauler F., Mittendorf J., Horváth E., De Vry J. Characterization of the diarylether sulfonylester (-)-(R)-3-(2-hydroxymethylindanyl-4-oxy)phenyl- 4,4,4-trifluoro-1-sulfonate (BAY 38-7271) as a potent cannabinoid receptor agonist with neuroprotective properties. J. Pharmacol. Exp. Ther. 302:2002;359-368.
20. Milton N.G.N. Anandamide and noladin ether prevent neurotoxicity of the human amyloid-β peptide. Neurosci. Lett. 332:2002;127-130.
21. Nagayama T., Sinor A.D., Simon R.P., Chen J., Graham S.H., Jin K., et al. Cannabinoids and neuroprotection in global and focal cerebral ischemia and in neuronal cultures. J. Neurosci. 19:1999;2987-2995.
22. Panikashvili D., Simeonidou C., Ben-Shabat S., Hanus L., Breuer A., Mechoulam R., et al. An endogenous cannabinoid (2-AG) is neuroprotective after brain injury. Nature. 413:2001;527-531.
23. 1 cannabinoid receptor knock-out mice. J. Neurosci. 22:2002;9771-9775.
24. Pertwee R.G. Cannabinoid receptors and pain. Prog. Neurobiol. 63:2001;569-611.
25. Pettmann B., Louis J.C., Sensenbrenner M. Morphological and biochemical maturation of neurones cultured in the absence of glial cells. Nature. 281:1979;378-380.
26. Romano C., Price M.T., Olney J.W. Delayed excitotoxic neurodegeneration induced by excitatory amino acid agonists in isolated retina. J. Neurochem. 65:1995;59-67.
27. Schlicker E., Kathmann M. Modulation of transmitter release via presynaptic cannabinoid receptors. Trends Pharmacol. Sci. 22:2001;565-572.
28. Schäbitz W.-R., Giuffrida A., Berger C., Aschoff A., Schwaninger M., Schwab S., et al. Release of fatty acid amides in a patient with hemispheric stroke. A microdialysis study. Stroke. 33:2002;2112-2114.
29. Sellström Å., Jacobsson S. Culturing CNS neurons: a practical approach to cultured embryonic chick neurons. Windhorst U., Johansson H. Modern Techniques in Neuroscience Research. 1999;327-338 Springer, Berlin.
30. Shen M., Thayer S.A. Cannabinoid receptor agonists protect cultured rat hippocampal neurons from excitotoxicity. Mol. Pharmacol. 54:1998;459-462.
31. Shen M., Piser T.M., Seybold V.S., Thayer S.A. Cannabinoid receptor agonists inhibit glutamatergic synaptic transmission in rat hippocampal cultures. J. Neurosci. 16:1996;4322-4334.
32. Sinor A.D., Irvin S.M., Greenberg D.A. Endocannabinoids protect cerebral cortical neurons from in vitro ischemia in rats. Neurosci. Lett. 278:2000;157-160.
33. 1 cannabinoid receptor: pharmacology and in vivo and in vitro effects of activation. J. Pharmacol. Exp. Ther. 297:2001;189-197.
34. 9- tetrahydrocannabinol, the main active compound in marijuana, against ouabain-induced in vivo excitotoxicity. J. Neurosci. 21:2001a;6475-6479.
35. van der Stelt M., Veldhuis W.B., van Haaften G.W., Fezza F., Bisogno T., Bär P.R., et al. Exogenous anandamide protects rat brain against acute neuronal injury in vivo. J. Neurosci. 21:2001b;8765-8771.